Use of Demineralized Bone Matrix in Hindfoot Arthrodesis

Michelson, James D.; Curl, Leigh Ann

doi:10.1097/00003086-199604000-00024

Cited by 75 publications

(64 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…405,419 Since his work, there has been increasing experience with DBM in both animals 123,140,272,405 and humans. 145,283 The sequence of events after implantation of DBM mirrors that of endochondral ossification. 405 Bone morphogenetic proteins 171…”

Section: Introductionmentioning

confidence: 99%

Treatment of osteochondral defects of the talus

Bergen

Leeuw

Dijk

2008

Revue de Chirurgie Orthopédique et Réparatrice de l'Appareil Mo

View full text Add to dashboard Cite

Section: Introductionmentioning

confidence: 99%

Treatment of osteochondral defects of the talus

Bergen

Leeuw

Dijk

2008

Revue de Chirurgie Orthopédique et Réparatrice de l'Appareil Mo

View full text Add to dashboard Cite

“…It has not been shown to produce efficient or durable fusion when used alone. More recently, the use has been expanding, with good results seen in ankle fusions when compared with ICBG [41] and some success with femoral nonunions or segmental defects.…”

Section: Demineralized Bone Matrixmentioning

confidence: 99%

Biologic adjuvants and bone: current use in orthopedic surgery

Smith

Goldstein

Ekstein

2015

Curr Rev Musculoskelet Med

View full text Add to dashboard Cite

Normal bone healing is a complex process that eventually restores original structure and function to the site of trauma. However, clinical circumstances such as nonunion, critical-sized defects, systemic bone disease, and fusion procedures have stimulated a search for ways to enhance this normal healing process. Biologics are an important part of this search and many, including bone marrow aspirate concentrate, demineralized bone matrix, platelet-rich plasma, bone morphogenic proteins, and platelet-derived growth factor, are currently in clinical use. Many others, including mesenchymal stem cells, parathyroid hormone, and Nel-like molecule-1 (NELL-1) will likely be in use in the future depending on the results of preclinical and clinical trials.

show abstract

“…DBM, on the other hand, provides an osteoconductive matrix and, if properly processed from a suitable host, can be osteoinductive. [1][2][3][4][5][6][7][8] DBM has been used successfully in many clinical situations, including long bone defects, 9-11 craniofacial defects, [12][13][14] joint surgery, 15,16 tumor surgery, 17,18 and the enhancement of spinal fusion, 8,19,20 but not all clinical studies have reported uniformly favorable results, especially when DBM has been compared to autograft. [21][22][23] For reasons not entirely understood, demineralization is necessary to maximize the osteoinductive properties of bone allograft.…”

Section: Introductionmentioning

confidence: 99%

Comparative evaluation of the osteoinductivity of two formulations of human demineralized bone matrix

Takikawa

Bauer

Kambic

et al. 2003

J Biomedical Materials Res

View full text Add to dashboard Cite

In the United States, demineralized bone matrix (DBM) is considered a transplantable tissue and therefore is regulated primarily by the American Association of Tissue Banks. Even though DBM is not subjected to the same regulations relative to performance claims as medical devices are, one would expect different processing methods might yield DBM preparations of different osteoinductive potential. The purpose of this study was to use an established athymic rat model to compare the osteoinductive properties of two commercially available human DBMs prepared using different methods but having essentially identical product claims. Sixteen female athymic rats were used to test equivalent volumes of two lots each of Grafton Putty (Osteotech, Inc., Eatontown, NJ), Osteofil (Regeneration Technologies, Inc., Alachua, FL), and rat DBM. At 28 days after implantation, qualitative and semiquantitative microscopy showed no significant differences in bone formation between the two lots from each source, but rat DBM produced significantly more bone than Grafton, which produced significantly more bone than Osteofil. Our results suggest that methods of graft processing may represent a greater source of variability than do differences among individual donors. Whether these differences relate to methods of demineralization, carrier, dose of DBM per volume, or to some other factor remains to be determined.

show abstract

Use of Demineralized Bone Matrix in Hindfoot Arthrodesis

Cited by 75 publications

References 17 publications

Treatment of osteochondral defects of the talus

Treatment of osteochondral defects of the talus

Biologic adjuvants and bone: current use in orthopedic surgery

Comparative evaluation of the osteoinductivity of two formulations of human demineralized bone matrix

Contact Info

Product

Resources

About